Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2004-09-10
2010-11-09
Hartley, Michael G (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S649000
Reexamination Certificate
active
07829595
ABSTRACT:
The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The present invention further relates to a method of manufacturing the pharmaceutical composition, as well as a method of treating a disease using the pharmaceutical composition.
REFERENCES:
patent: 5126145 (1992-06-01), Evenstad et al.
patent: 5981599 (1999-11-01), Moe et al.
patent: 6001884 (1999-12-01), Nemeth et al.
patent: 6011068 (2000-01-01), Nemeth et al.
patent: 6031003 (2000-02-01), Nemeth et al.
patent: 6172091 (2001-01-01), Cohen et al.
patent: 6211244 (2001-04-01), Van Wagenen et al.
patent: 6228807 (2001-05-01), Kuchikata et al.
patent: 6277788 (2001-08-01), Wright
patent: 6313146 (2001-11-01), Van Wagenen et al.
patent: 6316460 (2001-11-01), Creekmore et al.
patent: 6342532 (2002-01-01), Moe et al.
patent: 6363231 (2002-03-01), Manzer et al.
patent: 6387404 (2002-05-01), Oshlack et al.
patent: 6399100 (2002-06-01), Clancy et al.
patent: 6419954 (2002-07-01), Chu et al.
patent: 6432656 (2002-08-01), Del Mar et al.
patent: 6447809 (2002-09-01), Krumhar et al.
patent: 6495165 (2002-12-01), Thosar et al.
patent: 2001/0051636 (2001-12-01), Black et al.
patent: 2002/0015735 (2002-02-01), Hedden et al.
patent: 2002/0107406 (2002-08-01), Sakai et al.
patent: 2002/0123459 (2002-09-01), Ault et al.
patent: 2003/0035836 (2003-02-01), Shanghvi et al.
patent: 2003/0054041 (2003-03-01), Lemmens et al.
patent: 2005/0147670 (2005-07-01), Hsu et al.
patent: 0 933 354 (1999-08-01), None
patent: WO 93/04373 (1993-03-01), None
patent: WO 94/18959 (1994-09-01), None
patent: WO 95/11221 (1995-04-01), None
patent: WO 96/12697 (1996-05-01), None
patent: WO 97/41090 (1997-11-01), None
patent: WO 01/34562 (2001-05-01), None
William G Goodman, Gerald A. Hladik, Stewar A. Turner, Peter W. Blaisdell, David A. Goodkin, Wei Liu, Yousir M. Barri, Raphael M Cohen and jack W. Cobum, The Calcimimetic Agent AMG 073 Lowers Plasma parathryoid Hormone levels in Hemodialysis patients with secondary hyperparathyroidism, J. Am. Soc. Nephrology, 13, 1017-1024, 2002.
Amgen News Release, Internet Article: “Amgen Submitted New Drug Application for Cinecalcet HC1”, XP002313388, URL: http://www.amgen.com
ews
ews03/pressRelease030908a.pdf, Sep. 8, 2003, 2 pages.
Berge, Stephen, et al., “Pharmaceutical Salts,”J. Pharm. Sci., vol. 66, No. 1, pp. 1-19, Jan. 1977.
Drugs in R&D, “Cinecalcet: AMG 073, Calcimimetics— Amgen/NPS Pharmaceuticals, KRN 1493, NPS 1493,” vol. 4, No. 6, pp. 349-351, 2003.
Goodman, William G., et al., “The Calcimimetic Agent AMG 073 Lowers Plasma Parathyroid Hormone Levels in Hemodialysis Patients with Secondary Hyperparathyroidism,”J. Am. Soc. Nephrol, vol. 13, pp. 1017-1024, Apr. 2002.
Nemeth, Edward F., et al., Pharmacodynamics of the Type II Calcimimetic Compound Cinacalcet HCl,J. Pharmacol. Exp Therapeutics, vol. 308, No. 2, pp. 627-635, Feb. 2004.
Pattaragarn, Anirut, et al., “Effect of the Calcimimetic NPS R-467 on Furosemide- Induced Nephrocalcinosis in the Young Rat,”Kidney Internationa, vol. 65, pp. 1684-1689, 2004.
U.S. Food and Drug Administration, Internet Article: “FDA Approves First in a New Class of Drugs to Treat Hyperparathyroidism Associated with Renal Failure and in Patients with Parathyroid Cancer,”FDA Talk Paper, XP-002313389, http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01282.html), Mar. 8, 2004. 1 page, (retrieved by EPO Searching Authority on Jan. 11, 2005).
RxList, Inc., Internet Article: “Sensipar (Cinacalcet HCI) Tablets,” XP-002313390, www.rxlist.com/cgi/generic3/sensipar.htm), Aug. 12, 2004, 2 pages, (retrieved by EPO Searching Authority on Jan. 10, 2005.
NPS Pharmaceuticals, Internet Article: “NPS Drug Development: Product Development Pipeline,” XP-002313391, www.npsp.com/drug-development/pipline.php, Sep. 8, 2003, 2 pages, (retrieved by EPO Searching Authority on Jan. 12, 2005).
Alvarez Francisco J.
Ju Tzuchi R.
Lawrence Glen Gary
Lin Hung-Ren H.
Amgen Inc.
Foley & Lardner LLP
Hartley Michael G
Samala Jagadishwar R
LandOfFree
Rapid dissolution formulation of a calcium receptor-active... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rapid dissolution formulation of a calcium receptor-active..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rapid dissolution formulation of a calcium receptor-active... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4172506